{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:22:44Z","timestamp":1793467364387,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jgar.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T21:56:10Z","timestamp":1712440570000},"page":"190-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world evaluation of imipenem\/cilastatin\/relebactam across US medical centres"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Turzhitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-9583","authenticated-orcid":false,"given":"Jae S.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre H.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.03.002_bib0001","series-title":"Centers for Disease Control Prevention","article-title":"Antibiotic resistance & patient safety portal","year":"2019"},{"key":"10.1016\/j.jgar.2024.03.002_bib0002","series-title":"Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities","year":"2017"},{"key":"10.1016\/j.jgar.2024.03.002_bib0003","unstructured":"CDC. Antibiotic resistance threats in the United States. 2019."},{"key":"10.1016\/j.jgar.2024.03.002_bib0004","doi-asserted-by":"crossref","unstructured":"CDC. COVID-19: U.S. impact on antimicrobial resistance, special report 2022. 2023. https:\/\/dx.doi.org\/10.15620\/cdc:117915","DOI":"10.15620\/cdc:117915"},{"key":"10.1016\/j.jgar.2024.03.002_bib0005","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.03.002_bib0006","doi-asserted-by":"crossref","first-page":"e00169","DOI":"10.1128\/AAC.00169-18","article-title":"In vitro activity of imipenem-relebactam against clinical isolates of gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.002_bib0007","doi-asserted-by":"crossref","first-page":"ofab554","DOI":"10.1093\/ofid\/ofab554","article-title":"Early multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections","volume":"8","author":"Rebold","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0009","doi-asserted-by":"crossref","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-019-1522-7","article-title":"In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa","volume":"19","author":"Young","year":"2019","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2024.03.002_bib0011","series-title":"Premier healthcare database: data that informs and performs","author":"Sciences","year":"2020"},{"key":"10.1016\/j.jgar.2024.03.002_bib0012","first-page":"e01628","article-title":"Relationship between diagnostic method and pathogen detection, healthcare resource use, and cost in US adult outpatients treated for acute infectious gastroenteritis","author":"Moon","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2024.03.002_bib0013","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21105\/joss.02017","article-title":"Ggalluvial: layered grammar for alluvial plots","volume":"5","author":"Brunson","year":"2020","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.jgar.2024.03.002_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020\u20132021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.03.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00189-22","article-title":"In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART Surveillance Program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2024.03.002_bib0017","doi-asserted-by":"crossref","first-page":"ofy241","DOI":"10.1093\/ofid\/ofy241","article-title":"Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study","volume":"5","author":"McCann","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115172","article-title":"Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States","volume":"99","author":"Puzniak","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2024.03.002_bib0020","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.15562\/bmj.v12i1.3950","article-title":"Critical priority multidrug-resistant organisms (MDROs) secondary infection among COVID-19 patients: hidden threat during a pandemic? A retrospective study","volume":"12","author":"Syaiful","year":"2023","journal-title":"Bali Med J"},{"key":"10.1016\/j.jgar.2024.03.002_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12890-023-02315-9","article-title":"Risk factors and effect on mortality of superinfections in a newly established COVID-19 respiratory sub-intensive care unit at University Hospital in Rome","volume":"23","author":"Iacovelli","year":"2023","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jgar.2024.03.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac492.1055","article-title":"1223. The impact of the COVID-19 pandemic on the prevalence of multidrug-resistant organisms in veterans affairs nursing homes","volume":"9","author":"Sajib","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2024.03.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103335","article-title":"Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer","volume":"100","author":"Meng","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jgar.2024.03.002_bib0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jval.2019.03.001","article-title":"Real-world evidence, causal inference, and machine learning","volume":"22","author":"Crown","year":"2019","journal-title":"Value Health"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:27:10Z","timestamp":1718681230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"alternative-id":["S2213716524000559"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of imipenem\/cilastatin\/relebactam across US medical centres","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck & Co., Inc., Rahway, NJ, USA. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}